First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

S. Peters, A. Scherpereel, R. Cornelissen, Y. Oulkhouir, L. Greillier, M. A. Kaplan, T. Talbot, I. Monnet, S. Hiret, P. Baas, A. K. Nowak, N. Fujimoto, A. S. Tsao, A. S. Mansfield, S. Popat, X. Zhang, N. Hu, D. Balli, T. Spires, G. Zalcman

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743'. Together they form a unique fingerprint.

Medicine & Life Sciences